Penserra Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Penserra Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-280	Closed	-$75K	–	1485
2021 Q3	$75K	Buy	280 +3	+1%	+$721	﹤0.01%	920
2021 Q2	$71K	Buy	277 +2	+0.7%	+$554	﹤0.01%	894
2021 Q1	$82K	Sell	275 -1	-0.4%	-$311	﹤0.01%	719
2020 Q4	$70K	Buy	276 +174	+171%	+$45K	﹤0.01%	641
2020 Q3	$25K	Buy	+102	New	+$32.1K	﹤0.01%	710
2018 Q4	–	Sell	-56	Closed	-$51K	–	734
2018 Q3	$51K	Sell	56 -1,519	-96%	-$1.3M	﹤0.01%	534
2018 Q2	$1.15M	Buy	+1,575	New	+$1.82M	0.07%	190

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Penserra Capital Management's NKTR Position: Q4 2021 in Review

Penserra Capital Management sold out of Nektar Therapeutics (NKTR) in Q4 2021, closing a stake of 280 shares — an estimated $75K sold.

Penserra Capital Management first reported a position in NKTR in Q2 2018 and held it in 7 quarters. The position peaked at $1.15M in Q2 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q4 2021.

Penserra Capital Management reported no remaining Nektar Therapeutics position as of Q4 2021 after selling out during the quarter.
Penserra Capital Management sold 280 Nektar Therapeutics shares in Q4 2021, an estimated $75K.
Penserra Capital Management first reported a position in Nektar Therapeutics in Q2 2018 and held it in 7 quarters.
Penserra Capital Management's Nektar Therapeutics position peaked at $1.15M in Q2 2018.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.